Abstract
The identification of activating mutations in mTOR that explain an exceptional response in a patient with bladder cancer is the latest example of mechanistic insights that can be gleaned from analyzing exceptional responders in otherwise failed trials. The NCI plans to sequence 100 such exceptional responders to help identify other cancer-related mutations that could predict drug response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
